Association Between Sacubitril/Valsartan Initiation and Mitral Regurgitation Severity in Heart Failure With Reduced Ejection Fraction: The PROVE-HF Study

Circulation. 2022 Nov 22;146(21):1638-1640. doi: 10.1161/CIRCULATIONAHA.122.061693. Epub 2022 Oct 2.

James L Januzzi^{1

2}, Alaa Mabrouk Salem Omar^{3

4}, Yuxi Liu¹, Sean Murphy¹, Javed Butler^{5

6}, G Michael Felker⁷, Iliana L Piña⁸, Jonathan Ward⁹, Scott Solomon¹⁰, Johanna Contreras⁴

¹ Massachusetts General Hospital (J.L.J., Y.L., S.M.), Harvard Medical School, Boston.
² Baim Institute for Clinical Research, Boston, MA (J.L.J.).
³ Mount Sinai Morningside, New York, NY (A.M.S.O.).
⁴ Icahn School of Medicine at Mount Sinai, New York, NY (A.M.S.O., J.C.).
⁵ Baylor Scott and White Research Institute, Dallas, TX (J.B.).
⁶ University of Mississippi, Jackson (J.B.).
⁷ Duke University School of Medicine, Durham, NC (G.M.F.).
⁸ Thomas Jefferson University, Philadelphia, PA (I.L.P.).
⁹ Novartis Pharmaceuticals Corporation, East Hanover, NJ (J.W.).
¹⁰ Brigham and Women's Hospital (S.S.), Harvard Medical School, Boston.

No abstract available

Keywords: cardiac remodeling; health status; heart failure; mitral regurgitation; natriuretic peptides; prognosis; sacubitril/valsartan.

Publication types